NCT07320105 2026-01-06
Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)
Fujian Cancer Hospital
Phase 4 Recruiting
Clinical Trials
4 trialsNCT06793228 2025-01-27
Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT05878028 2024-05-23
L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC
Henan Cancer Hospital
Phase 2 Recruiting
NCT05192681 2022-01-14
Tislelizumab as Cross-line Treatment for Advanced NSCLC
Fujian Cancer Hospital
Phase 2 Unknown